Abstract
AIM: Osteosarcoma patients receive high doses of methotrexate (MTX). However, pharmacogenetic information remains limited and has mainly been investigated in leukemia so far.
PATIENTS & METHODS: We investigated the link between the MTHFR C677T genotype, toxicity levels (mucositis, MTX plasma level, hematological toxicity and hepatotoxicity) and survival of 48 pediatric osteosarcoma patients.
RESULTS: The TT genotype did not show more toxicity compared with the CC/CT genotype. However, plasma MTX levels were related with mucositis, but not with hematological toxicity, nor hepatotoxicity. Survival rates did not differ between homozygous and non-homozygous patients. Yet, homozygous patients had higher relapse risk.
CONCLUSION: The MTHFR C667T polymorphism is not predictive for toxicity or overall survival, but could be used for relapse risk stratification.
| Original language | English |
|---|---|
| Pages (from-to) | 787-795 |
| Number of pages | 9 |
| Journal | Pharmacogenomics |
| Volume | 18 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - 2017 |
| Externally published | Yes |
Keywords
- Adolescent
- Antimetabolites, Antineoplastic/administration & dosage
- Child
- Drug-Related Side Effects and Adverse Reactions/genetics
- Female
- Genotype
- Homozygote
- Humans
- Male
- Methotrexate/administration & dosage
- Methylenetetrahydrofolate Reductase (NADPH2)/genetics
- Osteosarcoma/drug therapy
- Pharmacogenetics/methods
- Polymorphism, Genetic/genetics
- Retrospective Studies